Vol. 18/No. 24 | OncologyLive

Molecular Subtypes Correlate With Outcomes in RCC

January 16, 2018

Molecular subtypes of clear-cell renal cell carcinoma were prognostic for outcomes after metastasectomy, with significant differences seen in overall survival and disease-free survival between groupings.

Progress for TNBC Seen Across Treatment Modalities

January 15, 2018

Although chemotherapy remains the mainstay of treatment for patients with triple-negative breast cancer, promising developments are unfolding on several fronts, including new ways of using existing therapies and the exploration of immunotherapy, novel antibodies, and agents targeting the PI3K/mTOR/AKT pathway.

Fresh Look at Gene Fusion Yields Clues in Low-Risk Prostate Cancer

January 10, 2018

Although gene fusions between the TMPRSS2 gene and ETS family of transcription factors in prostate cancer have been recognized for more than a decade, the clinical relevance of this fusion event continues to be debated among experts.

Where Overall Survival Falls Short as a Gauge

January 09, 2018

From the perspective of a patient and that patient’s family, it is completely understandable that the single most important goal of an antineoplastic strategy is to prolong survival and, if possible, produce a cure.

Practical Questions on Checkpoint Agents Arise

January 05, 2018

Despite the promising developments in this arena, many patients with cancer respond inadequately to immune checkpoint monotherapy, and others develop serious (grade 3-4) toxicities that require treatment cessation.